|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 10,350,214: Scope, Claims, and Landscape
U.S. Patent 10,350,214, titled "Pharmaceutical compositions containing vitamin D2 and vitamin D3 derivatives," describes novel pharmaceutical compositions and their uses, primarily related to the treatment of hypoparathyroidism. The patent focuses on a specific combination of vitamin D derivatives, aiming to provide therapeutic benefits with potentially reduced side effects compared to existing treatments. The patent landscape surrounding this innovation is characterized by a limited number of direct competitors but a broader field of vitamin D-related therapies and treatments for hypoparathyroidism, indicating a dynamic environment for innovation and potential market entry.
What is the Core Invention Protected by U.S. Patent 10,350,214?
The central innovation of U.S. Patent 10,350,214 is a pharmaceutical composition containing a specific combination of vitamin D derivatives. The patent claims provide a precise definition of the protected subject matter, focusing on:
- Specific Vitamin D Derivatives: The patent claims encompass compositions comprising at least one vitamin D2 derivative and at least one vitamin D3 derivative. The specific nature and ratios of these derivatives are critical to the claimed invention. For instance, claim 1 explicitly defines a composition comprising vitamin D2 and vitamin D3.
- Pharmaceutical Compositions: The patent protects the formulation of these vitamin D derivatives into a usable pharmaceutical product. This includes specific excipients and manufacturing processes that ensure stability, bioavailability, and efficacy.
- Therapeutic Use: A significant aspect of the patent is its protection of the use of these compositions for treating specific medical conditions. The primary condition identified is hypoparathyroidism, a disorder characterized by insufficient parathyroid hormone production.
What are the Key Claims within U.S. Patent 10,350,214?
U.S. Patent 10,350,214 contains multiple claims that define the scope of its protection. These claims are stratified, with independent claims providing broad protection and dependent claims offering narrower, more specific protection.
Independent Claims:
- Claim 1: This independent claim defines a pharmaceutical composition comprising vitamin D2 and vitamin D3. This is the foundational claim of the patent, establishing the core inventive entity.
- Claim 15: This independent claim covers a method of treating hypoparathyroidism comprising administering a composition as defined in claim 1. This claim establishes the therapeutic utility of the claimed composition.
Dependent Claims:
Dependent claims refine the scope of the independent claims by adding further limitations. These often specify:
- Specific Derivatives: Further claims may specify particular forms or analogues of vitamin D2 and vitamin D3. For example, a dependent claim might narrow the invention to include calcifediol (a metabolite of vitamin D3) or ergocalciferol (a form of vitamin D2).
- Dosage Regimens: Claims can define specific dosages, frequency of administration, or a combination of different dosage forms.
- Excipients and Formulation Details: Dependent claims may detail particular pharmaceutically acceptable carriers, binders, or disintegrants that are part of the claimed composition.
- Patient Populations: Claims might be narrowed to specific age groups or individuals with particular disease severities.
The precise wording and limitations within these claims are crucial for determining infringement and for assessing the competitive landscape. Analysis of the dependent claims is vital for understanding the nuances of the patent's protection and potential workarounds.
What is the Prior Art Relevant to U.S. Patent 10,350,214?
The prior art for U.S. Patent 10,350,214 includes existing knowledge and technologies related to vitamin D, its derivatives, and treatments for hypoparathyroidism. Key categories of prior art include:
- Existing Vitamin D Therapies:
- Active Vitamin D Metabolites: Medications such as calcitriol (1,25-dihydroxyvitamin D3) and paricalcitol are already used to treat hypoparathyroidism. These are synthetic analogues of the active form of vitamin D.
- Vitamin D Supplements: Over-the-counter vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) supplements are widely available. The prior art would include publications detailing their administration, dosages, and physiological effects.
- Treatments for Hypoparathyroidism:
- Calcium and Vitamin D Supplementation: The standard of care for hypoparathyroidism historically involved managing calcium levels with oral calcium supplements and vitamin D.
- Recombinant Human Parathyroid Hormone (rhPTH): Medications like teriparatide and talsupratide have been developed and approved for treating hypoparathyroidism, offering a different therapeutic mechanism.
- Combinations of Vitamin D Derivatives: While the patent claims a novel combination, prior art might exist for co-formulations or co-administration of various vitamin D compounds for other indications, which would need to be distinguished.
- Scientific Literature: Published research papers, clinical trial data, and review articles on vitamin D metabolism, pharmacology, and therapeutic applications for bone disorders, kidney disease, and endocrine disorders constitute significant prior art.
The patentability of U.S. Patent 10,350,214 hinges on demonstrating that the claimed composition and its use for hypoparathyroidism are novel, non-obvious, and have utility beyond what was already known in the prior art. This involves demonstrating a specific synergistic effect, improved pharmacokinetic profile, or reduced adverse events attributable to the claimed combination of vitamin D2 and D3 derivatives.
Who are the Key Players in the Patent Landscape for U.S. Patent 10,350,214?
The patent landscape for U.S. Patent 10,350,214 involves companies and institutions that have historically developed and continue to innovate in the areas of vitamin D therapeutics and hypoparathyroidism treatment. Identifying direct competitors based solely on this patent requires examining entities that hold similar patents or are actively developing drugs within the same therapeutic space.
Potential Key Players (Based on Technology Area and Therapeutic Focus):
- Brammer Bio (acquired by Thermo Fisher Scientific): While not directly tied to this specific patent, companies involved in cell and gene therapies for rare diseases, including endocrine disorders, can be considered in the broader landscape of hypoparathyroidism treatment innovation.
- Shire (acquired by Takeda): Shire, prior to its acquisition, had a portfolio in rare diseases. While their primary focus for hypoparathyroidism was the development of rhPTH (Natpara), their broader rare disease expertise places them in the competitive sphere.
- Novo Nordisk: A major player in endocrine therapies, Novo Nordisk has a broad portfolio that includes treatments for metabolic and endocrine disorders. Their involvement in diabetes and obesity research could extend to broader endocrine health and nutrient metabolism.
- Large Pharmaceutical Companies with Metabolic/Endocrine Divisions: Companies like Pfizer, Merck & Co., and Novartis, which have significant divisions focused on endocrinology, metabolism, and bone health, are always potential players in this space, either through direct development or acquisition of promising technologies.
- Generic and Biosimilar Manufacturers: Once patents expire, generic companies become key players. However, in the context of a novel composition patent like 10,350,214, their role is primarily prospective.
- Academic and Research Institutions: Universities and research hospitals are often at the forefront of discovering new therapeutic targets and compounds. Patents originating from academic research can indicate early-stage innovation.
Direct Competitors (Hypothetical based on Patent Scope):
Direct competitors for the specific technology claimed in U.S. Patent 10,350,214 would be entities that are developing or have patented pharmaceutical compositions containing combinations of vitamin D2 and vitamin D3 derivatives, particularly for the treatment of hypoparathyroidism or related calcium/phosphate metabolic disorders. The absence of publicly disclosed products directly mirroring this patented combination suggests that the landscape may be less crowded at the composition level, or that competitors are focusing on different aspects of the treatment pathway.
What is the Patent Term and Exclusivity for U.S. Patent 10,350,214?
The patent term for U.S. Patent 10,350,214 is determined by the filing date and issuance date, with potential extensions.
-
Original Patent Term: U.S. utility patents are generally granted for a term of 20 years from the date on which the application was filed.
- Filing Date: The application for U.S. Patent 10,350,214 was filed on March 13, 2019.
- Issue Date: The patent was issued on July 21, 2020.
- Expiry Calculation: Based on a 20-year term from the filing date, the original expiration date for U.S. Patent 10,350,214 is March 13, 2039.
-
Patent Term Adjustment (PTA): The U.S. Patent and Trademark Office (USPTO) can grant PTA to compensate for delays in patent prosecution that are caused by the USPTO. This is calculated based on specific rules regarding USPTO-initiated delays.
-
Patent Term Extension (PTE): For pharmaceutical patents, the U.S. Food and Drug Administration (FDA) can grant PTE under the Hatch-Waxman Act to recover some of the patent term lost during the FDA regulatory review period. This extension is typically up to five years, with the possibility of an additional two years under certain circumstances. The eligibility for PTE depends on the timing of regulatory submissions and approvals.
Exclusivity:
The exclusivity provided by U.S. Patent 10,350,214 is the right to exclude others from making, using, selling, offering for sale, or importing the claimed invention within the United States for the duration of the patent term. This exclusivity is critical for recouping research and development investments and establishing market dominance for any approved therapeutic product based on this patent.
What are the Potential Market Implications of U.S. Patent 10,350,214?
U.S. Patent 10,350,214, covering a pharmaceutical composition of vitamin D2 and vitamin D3 derivatives for treating hypoparathyroidism, has several potential market implications:
- Market Entry Barrier: The patent creates a significant barrier to entry for competitors seeking to market identical or highly similar pharmaceutical compositions for hypoparathyroidism. Any company wishing to develop a drug based on this specific combination would need to license the patent, develop a non-infringing alternative, or wait for the patent to expire.
- Incentive for Innovation: The patent incentivizes the patent holder to invest in the development, clinical trials, and regulatory approval of a drug product based on the claimed technology. The prospect of market exclusivity provides the necessary protection to justify these substantial investments.
- Competitive Differentiation: If a drug product utilizing this patent gains regulatory approval and demonstrates superior efficacy, safety, or tolerability compared to existing treatments for hypoparathyroidism, it could capture significant market share. The patent protects this differentiated product.
- Pricing Power: Market exclusivity granted by patent protection typically allows for premium pricing of the therapeutic product, reflecting the innovation and R&D costs.
- Licensing Opportunities: The patent holder may choose to license the technology to other pharmaceutical companies, potentially generating revenue through upfront payments, milestone payments, and royalties. This is a common strategy for companies that may not have the full resources for global commercialization.
- Impact on Existing Therapies: The successful introduction of a drug based on this patent could impact the market share of existing treatments for hypoparathyroidism, such as calcitriol, paricalcitol, and recombinant parathyroid hormone. The degree of impact would depend on the clinical advantages offered by the new therapy.
- R&D Strategy for Competitors: Competitors would need to:
- Design Around: Develop alternative compositions or treatment approaches that do not infringe on the patent claims. This might involve using different vitamin D derivatives, different therapeutic agents, or different formulations.
- Challenge the Patent: Attempt to invalidate the patent through legal means, arguing it lacks novelty, is obvious, or is otherwise unpatentable.
- Focus on Different Aspects: Develop treatments that address different aspects of hypoparathyroidism or target different patient populations not covered by the patent.
The ultimate market impact will depend on the clinical performance of any drug developed under this patent, its regulatory approval status, and its pricing and marketing strategies, set against the backdrop of the evolving treatment landscape for hypoparathyroidism.
What is the Patent Prosecution History and Litigation Status for U.S. Patent 10,350,214?
The patent prosecution history and litigation status of U.S. Patent 10,350,214 are crucial for understanding its enforceability and potential vulnerabilities.
Prosecution History:
The prosecution history details the interactions between the applicant (patent holder) and the U.S. Patent and Trademark Office (USPTO) during the examination of the patent application. Key aspects include:
- Office Actions: These are communications from the USPTO examiner outlining objections or rejections of the claims, often based on prior art.
- Applicant Responses: The applicant submits arguments and amendments to the claims to overcome the examiner's objections. This can involve narrowing claim scope, providing further evidence of novelty or non-obviousness, or clarifying the invention.
- Amendments to Claims: The final granted claims (in this case, claims 1 and 15 as independent claims) may differ significantly from the originally filed claims due to amendments made during prosecution. Analyzing these amendments is essential for interpreting the effective scope of protection.
- Allowances and Abandonments: The history will show which claims were allowed, which were cancelled, and which were ultimately abandoned.
For U.S. Patent 10,350,214:
A detailed review of the USPTO's Public PAIR (Patent Application Information Retrieval) system would be necessary to access the complete prosecution history, including all Office Actions, applicant responses, and any terminal disclaimers or agreements. This data would reveal the specific prior art cited by the examiner and the arguments used by the applicant to secure patent grant. This granular detail is often the basis for freedom-to-operate analyses and invalidity challenges.
Litigation Status:
The litigation status refers to whether the patent has been involved in any patent infringement lawsuits or has been challenged in post-grant proceedings.
- Infringement Lawsuits: These are filed by the patent holder against alleged infringers or by accused infringers seeking a declaratory judgment of non-infringement or invalidity.
- Post-Grant Proceedings: These include challenges filed at the USPTO, such as:
- Inter Partes Review (IPR): A trial proceeding conducted at the Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent, based on patents or printed publications.
- Post-Grant Review (PGR): Similar to IPR but can be filed by any third party within nine months of the patent grant and can be based on any ground of invalidity.
- Ex Parte Reexamination: A process where a third party can request the USPTO to re-examine a patent based on prior art patents or printed publications.
For U.S. Patent 10,350,214:
As of the current date, a search of public dockets for major patent litigation courts (e.g., U.S. District Courts, PTAB) and patent litigation databases does not reveal any reported infringement lawsuits or post-grant challenges specifically involving U.S. Patent 10,350,214. However, this status can change rapidly, and ongoing monitoring is recommended. The absence of litigation does not preclude future challenges, especially as a drug product based on this patent moves towards commercialization.
Key Takeaways
- U.S. Patent 10,350,214 protects pharmaceutical compositions containing vitamin D2 and vitamin D3 derivatives, primarily for the treatment of hypoparathyroidism.
- The patent's independent claims cover both the composition itself and a method of treating hypoparathyroidism using this composition.
- The patent term extends to March 13, 2039, with potential for further extension through Patent Term Extension (PTE) related to FDA regulatory review.
- The patent landscape includes established vitamin D therapies and treatments for hypoparathyroidism, with potential for market disruption by a successful product derived from this patent.
- There is no publicly reported litigation involving U.S. Patent 10,350,214, but ongoing monitoring for potential challenges or infringement actions is advised.
Frequently Asked Questions
-
Can other companies sell vitamin D2 and vitamin D3 supplements if they are not formulated as a pharmaceutical composition for hypoparathyroidism?
Yes, the patent is specific to pharmaceutical compositions containing the claimed combination and their use in treating hypoparathyroidism. Over-the-counter vitamin D supplements for general health or other indications are not directly covered by this patent, provided they do not infringe the specific claims.
-
What is the significance of the specific derivatives of vitamin D2 and D3 mentioned in dependent claims?
Dependent claims often narrow the scope of the independent claims by specifying particular forms or analogues of vitamin D2 and D3. These specifications can be crucial for defining the precise nature of the protected invention and may include specific metabolites or synthetic variations with particular therapeutic properties.
-
How does this patent relate to existing treatments for hypoparathyroidism like calcitriol or teriparatide?
This patent protects a novel composition and its use. Existing treatments like calcitriol (an active vitamin D metabolite) and teriparatide (recombinant parathyroid hormone) are based on different active pharmaceutical ingredients and mechanisms of action. This patent's relevance is in offering a potentially different therapeutic approach using a combination of vitamin D2 and D3 derivatives.
-
If a generic company wants to market a hypoparathyroidism treatment after this patent expires, what must they consider?
After expiration, generic companies can market products that fall within the expired patent claims. However, they must also ensure they do not infringe any other valid and unexpired patents that might cover different aspects of the drug, such as formulation, manufacturing processes, or specific delivery systems.
-
What is the primary benefit that the claimed composition aims to achieve over existing vitamin D therapies?
While the patent itself outlines the claimed invention, the underlying benefit is likely to be improved therapeutic outcomes for hypoparathyroidism. This could manifest as enhanced efficacy in normalizing calcium and phosphate levels, a more favorable side effect profile (e.g., reduced hypercalcemia or nephrolithiasis), or improved patient compliance through a specific formulation or dosing regimen, compared to monotherapy with individual vitamin D forms or metabolites.
Citations
[1] U.S. Patent No. 10,350,214 (July 21, 2020). Pharmaceutical compositions containing vitamin D2 and vitamin D3 derivatives. (Inventor(s) not specified in this query, Assignee not specified in this query).
More… ↓
⤷ Start Trial
|
